News

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer ...
The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized the FDA and was a ...